ArticleClinicoEconomics and outcomes research : CEOR2026
Pharmaceutical Manufacturing in China Innovation Performance: A Dynamic QCA Analysis Based on the WSR Perspective.
Article in ClinicoEconomics and outcomes research : CEOR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to investigate the theoretical foundations and driving mechanisms of innovation performance in the Chinese pharmaceutical manufacturing industry, offering theoretical and practical insights for enhancing the industry's innovation capacity and global competitiveness. Patients and Methods: Drawing upon the "Wuli-Shili-Renli" (WSR) systems methodology and a configurational perspective, this study employs dynamic Qualitative Comparative Analysis (QCA) to analyze Chinese provincial panel data spanning 2015-2021. The study explores the configurational effects of influencing factors across three dimensions-digital economy, environmental regulation, and social capital-on the innovation performance of the pharmaceutical manufacturing industry across 30 Chinese provinces and municipalities. Results: (1) The consistency scores for all antecedent conditions were below 0.9, indicating that no single factor constitutes a necessary condition for high innovation performance in the pharmaceutical manufacturing industry. (2) Three effective configurational paths driving high innovation performance were identified: the "dual-driven", "multiple-dominant", and "balanced coordination" paths. The overall solution consistency was 0.938, with an overall solution coverage of 0.511. (3) Temporally, configuration consistency exhibited a marked decline in 2017 and 2019, dropping below 0.9. (4) Spatially, the "balanced coordination" path achieved the highest provincial coverage, accounting for approximately 60%. Meanwhile, the "multiple-dominant" path revealed significant regional disparities, underscoring the need for most provinces to promote collaborative innovation within the industry. Conclusion: The integration of the "Wuli-Shili-Renli" (WSR) systems methodology with dynamic fuzzy-set Qualitative Comparative Analysis (fsQCA) transcends the limitations of single-paradigm research. This study offers two primary contributions. First, it provides a robust theoretical framework for analyzing high innovation performance in the Chinese pharmaceutical manufacturing industry, thereby enriching the international innovation management literature. Second, it serves as a cross-cultural exemplar, synthesizing Eastern systems thinking with Western empirical methods to advance the global discourse on pharmaceutical innovation. Furthermore, the findings offer actionable insights for policymakers and stakeholders to foster high-quality development and enhance the global competitiveness of the pharmaceutical industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.